HOME >> MEDICINE >> NEWS
Adams Respiratory Therapeutics and Hollister-Stier Laboratories to co-promote ALLERx(TM) dose pack

Chester, New Jersey April 5th, 2004 Adams Respiratory Therapeutics has formed an alliance with Hollister-Stier Laboratories LLC to promote Adams' ALLERxTM Dose Pack, a day/night treatment regimen for symptoms associated with allergic rhinitis, non-allergic rhinitis, vasomotor rhinitis and the common cold.

With the HollisterStier team calling on over 3,000 Allergists and Otolaryngologists nationally and Adams continuing to focus on Primary Care physicians, this alliance is designed to greatly heighten awareness of ALLERxTM Dose Pack as an important treatment option.

"We're excited to be working in concert with HollisterStier," remarked Mike Valentino, President and CEO of Adams Respiratory Therapeutics. "This co-promotion will expose additional physicians to the unique profile and benefits of ALLERxTM Dose Pack. HollisterStier's longstanding rapport with these important physician segments will be a key element in making this a successful venture."

"Having a product with the unique attributes of ALLERxTM Dose Pack will certainly strengthen our portfolio and create a real marketing opportunity for both parties," agreed Anthony D. Bonanzino, Ph.D., President & CEO of HollisterStier.

Located in Spokane, Washington, HollisterStier is a worldwide leader in the manufacture of allergenic extracts, targeted primarily at treating allergy and asthma. Their customer base includes over 3,000 Allergists/Immunologists and Otolaryngologists that specialize in allergic disease. HollisterStier enjoys a longstanding, close franchise with this group of specialists. In addition to its Allergy Business, HollisterStier is a nationally recognized contract manufacturer of sterile injectable vials, syringes and lyophilized products for the pharmaceutical and biopharmaceutical industries.

Headquartered in Chester, New Jersey, Adams Respiratory Therapeutics develops, markets and sells prescription and non-p
'"/>


5-Apr-2004


Page: 1 2

Related medicine news :

1. Respiratory infections, not air pollution, pose winter health threat for children with asthma
2. Respiratory therapists twice as likely to have asthma than other therapists
3. Respiratory health endowment to coordinate public education about asthma
4. Antibiotic Prophylaxis Could Help Prevent Respiratory Infections in the Critically Ill
5. 2005 Pharmacology, Therapeutics, & Toxicology Research Award
6. 2004 Pharmacology/Therapeutics/Toxicology Award to Haas

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology:
Cached News: